


PHARMACEUTICAL 2022

Xenetic Biosciences Inc. Rank 164 of 475







PHARMACEUTICAL 2022



Xenetic Biosciences Inc. Rank 164 of 475

The relative strengths and weaknesses of Xenetic Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenetic Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 128% points. The greatest weakness of Xenetic Biosciences Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is -25%, being 251% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	18,723
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,421
Liabilities, Non-Current	0
Other Assets	1,092
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	102
Property and Equipment	0
Research and Development	3,163
Revenues	1,161
Selling, General and Administrative Expense	3,744

Output Variable	Value in 1000 USD
Assets	19,815
Liabilities	1,421
Expenses	6,907
Stockholders Equity	18,394
Net Income	-5,645
Comprehensive Net Income	-5,645
Economic Capital Ratio	-25%